Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta 1a.

C Pozzilli1, T Koudriavtseva

  • 1Dipartimento di Scienze Neurologiche, I Clinica Neurologica, Università di Roma La Sapienza, Italy.

Bailliere'S Clinical Neurology
|April 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors.

Multiple sclerosis and related disorders·2023
Same author

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2022
Same author

Ponesimod to treat multiple sclerosis.

Drugs of today (Barcelona, Spain : 1998)·2021
Same author

A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis.

AJNR. American journal of neuroradiology·2021
Same author

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

Journal of neurology·2018
Same author

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

European journal of neurology·2018
Same journal

Remyelination in demyelinating disease.

Bailliere's clinical neurology·1999
Same journal

Other immunomodulatory therapies in multiple sclerosis.

Bailliere's clinical neurology·1999
Same journal

Copolymer-1.

Bailliere's clinical neurology·1999
Same journal

Treatment of multiple sclerosis with interferon beta 1b.

Bailliere's clinical neurology·1999
Same journal

The cause and management of bladder, sexual and bowel symptoms in multiple sclerosis.

Bailliere's clinical neurology·1999
Same journal

Spasticity, ataxia and fatigue in multiple sclerosis.

Bailliere's clinical neurology·1999
See all related articles

Interferon beta-1a (IFN-beta 1a) effectively reduces relapses and disability worsening in multiple sclerosis (MS) patients. MRI scans confirm reduced lesion activity, with generally mild side effects observed.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) pathogenesis involves complex immune dysregulation.
  • Immunoregulatory agents are being explored as therapeutic strategies for MS.
  • Interferon beta has emerged as a potential treatment option.

Purpose of the Study:

  • To evaluate the efficacy of interferon beta-1a (IFN-beta 1a) in patients with relapsing-remitting MS.
  • To assess the impact of IFN-beta 1a on clinical disease activity and disability progression.
  • To correlate clinical findings with magnetic resonance imaging (MRI) outcomes.

Main Methods:

  • Clinical trial involving patients with relapsing-remitting MS.
  • Administration of IFN-beta 1a.

Related Experiment Videos

  • Assessment of exacerbation rates and disability worsening over a 2-year period.
  • Magnetic resonance imaging (MRI) to evaluate lesion activity (Gd-enhancing and T2-weighted lesions).

    • Main Results:

    • IFN-beta 1a significantly reduced the rate of MS exacerbations.
    • Treatment with IFN-beta 1a slowed the sustained worsening of disability over 2 years.
    • MRI demonstrated a significant decrease in Gd-enhancing lesions and new T2 lesions.
    • IFN-beta 1a was generally well-tolerated, with mild and transient adverse events.

    Conclusions:

    • IFN-beta 1a is an effective disease-modifying therapy for relapsing-remitting MS.
    • The treatment offers both clinical and radiological benefits.
    • Further research is warranted to fully elucidate the therapeutic potential of IFN-beta 1a in MS.